Related Experiment Video

Updated: Aug 15, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

[Hypertrophic cardiomyopathy]

Thomas Scheffold1, Priska Binner, Jeanette Erdmann

  • 1Institut für Herz-Kreislaufforschung an der Universität, Witten/Herdecke. scheffold@herz-kreislaufforschung.de

Herz
|September 20, 2005
PubMed

Insights

Hypertrophic cardiomyopathy (HCM) is a common genetic heart disease often inherited. Early risk stratification for sudden death (SD) and further prospective studies are crucial for improved patient management and outcomes.

Area of Science:

  • Cardiology
  • Genetics
  • Myocardial Diseases

Context:

  • Hypertrophic cardiomyopathy (HCM) is a prevalent genetic heart disease affecting 0.2% of the population.
  • It is characterized by heterogeneous genetic causes, clinical manifestations, and disease progression.
  • Familial autosomal dominant inheritance is observed in approximately 60% of cases, often linked to mutations in specific genes.

Purpose:

  • To review the current understanding of hypertrophic cardiomyopathy (HCM), including its genetic basis, diagnosis, and management.
  • To highlight the heterogeneity of the disease and the need for improved risk stratification, particularly for sudden death (SD).
  • To identify gaps in current research and emphasize the necessity for large-scale prospective studies.

Summary:

  • HCM diagnosis relies heavily on echocardiography, with emerging roles for MRI and molecular genetic testing.
  • Prognosis is variable, influenced by hypertrophy extent and genetic mutations; SD is a significant risk in younger individuals.
  • Therapeutic strategies include medication (calcium antagonists, beta-blockers), interventional procedures (TASH/PTSMA, myectomy), and in end-stage cases, heart transplantation.

Impact:

  • Improved understanding of HCM's genetic underpinnings and heterogeneous nature.
  • Highlights the critical need for systematic risk stratification to prevent sudden death (SD) in HCM patients.
  • Underscores the demand for more prospective studies and registries to refine diagnostic and therapeutic guidelines for HCM.

More Related Videos

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...